Considering that the validation of previous GWAS findings is an essential step to tailor treatments for RA and to approach personalized medicine, we aimed to validate the association of GWAS-identified variants for response to TNF inhibitors (TNFi) in a two-stage nested case-control association study including a cohort of 1361 anti-TNF naïve RA patients ascertained through the REPAIR consortium and DANBIO registry and an independent replication cohort of 706 RA patients treated with TNFi from the DREAM registry. The gene discussed is TNF; the disease is rheumatoid arthritis.